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Background: Despite calcium channel blockers — long acting nitrates (CaCH-LAN), ~20% of patients with
Prinzmetal's Variant Angina (PVA) retain intractable angina. The endothelial nitric oxide synthase (eNOS) T-786C
polymorphism, more common in PVA than normal subjects, decreases the conversion of L-arginine to nitric oxide
(NO), promoting coronary artery spasm (CAS)-angina.
Methods: PCRmeasures for the eNOS T-786C polymorphism were done in 59 PVA patients with intractable angina
despite CaCH-LAN. Using the Seattle Angina Questionnaire (SAQ), effects of 9 g L-arginine/day were prospectively
assessed in 28patientswith ≥3 visits, pre-treatment entry and ≥2 follow-ups at 1 and5months, and in 31 additional
patientswith 2 visits, entry and 7.7months on L-arginine. This allowed an assessment of response to L-arginine in 59
patients at entry and 12 months later (last follow-up).
Results: In the cohort of 59 patients, 47% of eNOS alleles were mutant vs. 20% in 72 normal controls, p b .0001.
Compared to pre-treatment baseline, all 5 SAQ components improved in 28 patients at 1 (p ≤ .02 for all) and
5 months (p ≤ .03 for all) on L-arginine treatment, and improved in the 59 patients after 12 months on L-arginine,
p ≤ .002 for all. The eNOS mutation was a signiﬁcant positive independent determinant of reduction in anginal
symptoms,p=.0002. Patients hetero- andhomozygous for the eNOSmutationhadgreater improvement in anginal
symptoms.
Conclusions: In patients with intractable angina despite CaCH-LAN, the eNOS T-786C mutation appears to facilitate
CAS via reduced NO production, a condition susceptible to treatment with L-arginine.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prinzmetal's Variant Angina (PVA) is listed as a rare disease by the
Ofﬁce of Rare Diseases of the National Institutes of Health (NIH), affect-
ing less than 200,000 people in the US population. PVA has been found
in about 40% of all anginal patients in Japan [1]. PVA was ﬁrst described
in 1959 by Prinzmetal et al. [2] as angina occurring at rest, associated
with ST-segment elevation. Prinzmetal et al. hypothesized that thelial nitric oxide synthase; PVA,
a; CAS, coronary artery spasm;
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d Ltd. This is an open access article unangina was caused by an increased tonus or spasm at the level of coro-
nary stenosis [2]. Subsequently, coronary angiography during sponta-
neous angina attacks demonstrated coronary artery spasm (CAS)
[3–5]. The diagnostic criteria include ergonovine or acetylcholine-
induced CAS during coronary angiography or transient ST elevation
during anginal attacks in patients with normal coronary angiography
[6]. PVA has adverse cardiovascular outcomes, as documented in a re-
cent 12-year follow-up study of 273 patients where total mortality, car-
diac mortality, and myocardial infarction (MI) rates were 24%, 7%, and
6%, with yearly incidence rates of 2%, 0.6%, and 0.5%, respectively [7].
Deﬁcient release of nitric oxide (NO) is an important factor in the
pathogenesis of CAS [8] in PVA [4,9–11]. A thymine replacement by
cytosine at nucleotide -786 of the endothelial NO synthase (eNOS)
gene reduces eNOS gene promoter activity and reduces levels of the
potent coronary artery vasodilator, NO [12]. Cigarette smoking is syner-
gistic with the T-786C polymorphism of the eNOS gene for coronary
spasm [13], and for arterial stiffness [14]. The eNOS T-786C mutation
enhances the response to the constrictor effects of acetylcholine by
reducing endothelial NO synthesis [15].der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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quently developing chest pain at rest, most notably in the earlymorning
hours [2,16–19]. The duration of the pain normally lasts anywhere from
5 to 15min. Prolonged ischemia caused by CAS can progress tomyocar-
dial infarction, arrhythmias, and even sudden death in up to 10% of
patients [18–22].
The initial treatment for PVA is high dose, long acting calcium
channel antagonists [23]. To prevent recurrent attracts, long acting
nitrates such as nitroglycerin are often helpful [24,25]. However, Kosugi
et al. reported that long term nitrate treatment was an independent
positive predictor of cardiac events [26]. Despite aggressive medical
therapy, it has been estimated that from 20% to 60% of patients with
PVA fail to respond to treatment [23,27,28].
Acute intravenous L-arginine infusion improves endothelial function
in patients with angina pectoris and normal coronary arteriograms [29].
In 10 patients with intractable angina pectoris, Blum et al. [30] gave 9 g
of L-arginine/day, and reported “…a signiﬁcant clinical improvement in
7 of 10 patients, whichwas associated with a signiﬁcant decrease in cell
adhesionmolecule and proinﬂammatory cytokine levels.”Angelini et al.
[31] reported that 3 g/day of L-arginine, alongwith 60mgnifedipine and
60mg isosorbide resolved anginal symptoms in a patient with CAS and
myocardial bridging. Schulman et al. [32] gave 9 g/day of L-arginine in a
double blind trial to 153 patientswith acute ST-segment elevationmyo-
cardial infarction with PVA not speciﬁed, and reported no beneﬁts, but
there was an increase in mortality in the L-arginine group. Schulman
et al. [32] concluded that L-arginine should not be given following
acutemyocardial infarction. However, in ameta-analysis of randomized
controlled clinical trials of L-arginine supplementation, Sun. et al. [33]
reported that L-arginine had no effect on clinical outcomes of patients
with acute myocardial infarction.
In 43 cases withwell-documented PVA, we previously reported [10]
that the mutant eNOS T-786C allele frequency in patients was 29%
vs. 14% in 43 healthy normal controls (p= 0.016). In 19 patients with
persistent angina symptoms despite conventional nitrate–calcium
channel blocker therapy, on treatment with 9 g/day L-arginine to
increase NO production, 10 (53%) became angina-free, 3 (16%) were
improved but not angina free, and 6 (32%) had no change in their
angina. Using L-arginine, the Seattle Angina Questionnaire (SAQ) phys-
ical ability score increased from a median of 42 to 72 of a total possible
score of 100 (p=0.01), satisfaction with symptom reduction increased
from53 to 61 (p=0.004), and the perception of quality of life as accept-
able increased from 29 to 50 (p= 0.001). We concluded that the eNOS
T-786C mutation appears to facilitate CAS via reduced NO production, a
condition susceptible to treatment with L-arginine.
In our second study of PVA [11], we evaluated 27 patients with well-
documented PVA, compared to 72 healthy controls who did not differ
by race or gender. Of the 27 cases, 7 (26%) were homozygous for wild-
type normal eNOS (CC), 13 (48%) were T-786C heterozygotes (TC),
and 7 (26%) were T-786C homozygotes (TT) vs. controls, 44 (61%) CC,
27 (38%) TC, and 1 (1%) TT, p b 0.0001. The mutant eNOS T-786C allele
frequency in PVApatientswas 27/54 (50%) vs. 29/144 (20%) in controls,
p b 0.0001. L-Arginine (9 g/d) was given for a median of 4.7 months
in 16 PVA patients with symptomatic angina despite conventional
nitrate–calciumchannel blockers. Using the SAQ, satisfactionwith symp-
tom remission rose (median) from 50% to 100% (p=0.004), satisfaction
with angina frequency reduction rose from 65% to 80% (p=0.02), satis-
faction with treatment for symptoms rose from 38% to 88% (p=0.001),
and perception of overall life status rose from 25 to 71% (p= 0.0002).
On L-arginine (a median of 4.7 months), in 20 patients, none had
worsening of angina, and of 7 patients whose angina totally resolved,
eNOS T-786C homozygosity was over-represented.
In the current study, we assessed as to what degree the endothelial
NO synthase (eNOS) T-786C polymorphism, leading to reduced NO
production and CAS, was associatedwith PVA. Using the SAQ, the effects
of 9 g L-arginine/day were prospectively assessed in 28 patients with
≥3 visits, pre-treatment entry and 2 follow-ups at 1 and 5 months,and a ﬁnal visit (a median of 19 months), and in 31 additional patients
with 2 visits, at entry and 7.7 months on L-arginine. This allowed an as-
sessment of response to L-arginine in 59 patients at entry and last
follow-up (a median of 12 months).
2. Materials and methods
The present study was conducted according to the principles of the
Declaration of Helsinki with signed informed consent, following a pro-
tocol approved by the institutional review board of The Jewish Hospital




Fifty-nine not previously reported [10,11] patients with PVA and
intractable angina despite conventional calcium channel blocker–
nitrate therapy were studied in the sequence of their referral by their
cardiologists and physicians. The diagnosis of PVA was conﬁrmed by
transient ST elevation during angina attacks at rest in patients with nor-
mal coronary angiography, or by ergonovine or acetylcholine-induced
coronary vasospasm during coronary angiography. Ergonovine–
acetylcholine-induced CAS was deﬁned by reproduction of anginal
symptoms, and/or ECG changes, and/or coronary artery lumen reduction.
Information was obtained from all patients on current anti-angina
drug therapy for their PVA, current and previous smoking, diabetes, pre-
vious MI, and stent placement, to facilitate the assessment of possible
interactions between the eNOS T786C genotype and environment.
Patients were asked to ﬁll out the SAQ [34] at their ﬁrst pre-
treatment assessment, and after 1 month and then every 3 months on
9.0 g/day oral L-arginine (Arginaid), [10,11]. Patients were instructed
to retain their usual anti-angina therapy with long acting nitrates and
calcium channel blockers unchanged during the study period to allow
assessment of changes in angina on treatment with L-arginine.
We focused on 59 patients with intractable angina despite conven-
tional nitrate–calcium channel blocker therapy who had pre-L-arginine
entry data and had ≥1 follow-up on therapy with 9 g L-arginine/day
(a median of 12 months), and on 28 of these 59 patients who had
≥2 follow-ups, a median of 1 and 5 months on therapy, and a ﬁnal
follow-up at a median of 19.4 months.
2.1.2. Controls
Seventy-two healthy normal adults included 40 previously described
healthy adult hospital personnel [35,36], and 32 healthy subjects evalu-
ated during family studies of hyperlipidemic patients. A detailedmedical
history was obtained in all 72 controls, who were entirely free of coro-
nary heart disease, and had never experienced angina.
2.1.3. Laboratory methods
As previously described [37], after an overnight fast, blood was
drawn in tubes containing ethylenediaminetetraacetic acid and the
deoxyribonucleic acid (DNA) was extracted for subsequent analysis of
the T-786C eNOS polymorphism. DNA was isolated with the Capture
Column (Gentra Systems, Minneapolis, MN). PCR measures of T-786C
eNOS [38] was carried out by previously published methods. The for-
ward primer for the eNOS polymorphism [37] was 5-tgg aga gtg ctg
gtg tac cca-3, the reverse primer was 5-gcc tcc acc ccc acc ctg tc-3.
One hundred nanograms of patient DNA was denatured at 95 °C for
5 min, then 33 cycles: 95 °C for 0.5 min, 63 °C for 0.5 min, and then
72 °C for 0.5 min. The product was digested withMsp I as per supplier's
instructions (New England Biolabs, Beverly, MA).
The products of the PCR reactions were then electrophoresed on
a 10% polyacrylamide gel and the bands visualized with ethidium bro-
mide [37].
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All statistical analyses were done using SAS for Windows, 9.4
(2002–2012, SAS Institute, Cary, NC). Distributions of the eNOS geno-
types and mutant alleles were compared between patients and race
comparable healthy normal controls by Mantel-Haenszel χ2 and χ2
analyses. Odds ratios with 95% conﬁdence intervals were calculated
for heterozygous/homozygous eNOS mutations vs. wild-type normal
between patients and controls. Since patients were older, and more
likely to be female than controls, logistic regression models were used
to evaluate the odds ratio adjusted for age, race, and gender.
SAQ scores at study entry and on 9 g oral L-arginine/day were com-
pared by paired Wilcoxon tests.
Based on current observed data, an increase in satisfaction with
symptom remission from 50% to 75% (SD = 32%, correlation = 0.1),
with paired comparisons between pre-treatment baseline and on L-
arginine for 1 and 5 months, we calculated sample size. To detect a sig-
niﬁcant difference in symptoms on L-arginine therapy vs. pre-treatment
baseline, at least 26 patients would be needed for signiﬁcance level =
0.05 with power of 80%.
Associations of eNOST-786C genotypeswith changes in angina symp-
toms in 59 patients after a median of 12 months on 9 g oral L-arginine/
day were assessed by ANOVA adjusted for age, gender, and follow-up
duration.
To assess independent determinants for the changes in SAQ scores,
linear regressions were ﬁtted by stepwise selections (SLE = .15,
SLS = .05) from the potential explanatory variables: gender, age, age
when angina ﬁrst started, follow-up duration, and eNOS genotype (CC,
TC, and TT).
3. Results
PCR measures for the eNOS T-786C polymorphism were done in 59
PVA patients with intractable angina despite CaCH-LAN (Table 1,
Fig. 1). Using the SAQ, effects of 9 g L-arginine/day were prospectively
assessed in those 28 of 59 patients who had ≥3 visits, at pre-treatment
entry and at the 1st and 2nd follow-ups at 1 and 5 months (median)
(Table 2, Fig. 2), and in all the 59 patients from entry to last follow-up
(median 12 months) on L-arginine (Tables 3 and 4, Fig. 3).Table 1
Demography of 59 patients with Prinzmetal's Angina at study entry.
59 patients with Prinzmetal's Angina
Race W 58 (98%), Hispanic 1
Sex F 43 (73%), M 16 (27%)
Age 54 ± 13, median 54, range 14–74
Angina, age at ﬁrst development 47 ± 12, median 48, range 12–72
Smoke Never 46 (78%) 12 (20%) previously, 1
Diabetes No 57 (97%), Y 2 (3%)
MI No 37 (63%), Y 22 (37%)
Stent No 52 (88%), ≥1 7 (12%)
eNOS TT 12 (20%), TC 32 (54%), CC 15 (25%
CC wild-type normal, TC heterozygou
Family member had angina No 47 (80%), Yes 12 (20%)
Seattle Angina Questionnaire scores. All scores range from 0 to 100, the higher, the better
A. Physical ability score
B. Symptom remission compared to 4 weeks ago
C. Angina frequency less during the past 4 weeks
D. Satisfaction with treatment for symptoms
E. Perception of overall life status
Angina frequency during the past 4 weeks (question C) at pre-L-arginine treatment, study
Score 1 (≥4 times/day) 2 (1–3 times/day) 3 (≥3 times/week)
n (%) 15 (25%) 11 (19%) 10 (17%)The 59 patients with PVA included 43women and 16men, 58white,
1 Hispanic, median age 54, ranging from 14 to 74 years. The clinical
characteristics of the patients are summarized in Table 1. Of the 59
patients, PVA was diagnosed by coronary artery spasm in response to
ergonovine injection in 2 (3%), in response to acetylcholine injection
in 1 (2%), and by transient ST elevation during angina attacks at rest in
56 patients (95%) with normal coronary angiography.
At study entry,mediandaily doses of calciumchannel blockers in the
59 patients included the following calcium channel blockers, nifedipine
80 mg, diltiazem 210 mg, amlodipine 5 mg, and verapamil 120 mg,
and for long acting nitrates, isosorbide 75 mg. These regimens were
unchanged throughout follow-up, by study design.
Cases were much more likely than controls to be homozygous
and heterozygous for the eNOS T786C mutation (Table 1, Fig. 1).
Forty-seven percent of the eNOS alleles in the 59 patients weremutant,
vs. 20% in controls, p b .0001, Fig. 1.
In the 59 cases, the odds ratio being heterozygous/homozygous for
the eNOS T786C polymorphism vs. wild-type normal for patients vs.
controls was 4.94, with 95% CI 2.30–10.6, p b .0001.
The 59 cases did not differ from the 72 healthy normal controls by
race (p = 0.4), but had more females (p = 0.04), and were older, a
median of 54 vs. 40 years, p b .0001.
Comparing the 59 cases vs. the 72 healthy normal controls, by
logistic regression with eNOS genotype (2 categories TT/TC vs. CC)
as the dependent variable and race, gender, age and group (case =
1, control = 0) as explanatory variables, race, gender, and age were
not signiﬁcant determinants of eNOS genotype (p N 0.4), while only
case status was signiﬁcant (adjusted OR = 5.25, 95% CI 2.19–12.6,
p = .0002).
The current 59 PVA cases did not differ fromour previously reported
27 PVA cases [11] by the eNOS genotype, 12 (20%) TT, 32 (54%) TC in 59
cases vs. 7 (26%) TT, 13 (48%) TC in the 27 cases (p = .8), and did not
differ by the percentage of patients with mutant alleles, 47% vs. 50%
(p= .8). The current 59 cases did differ from our previously published
43 cases [10] in regards to the eNOS genotype: 12 (20%) TT, 32 (54%)
TC in the current 59 cases vs. 3 (7%) TT, 19 (44%) TC in 43 cases, p =
.007, and also differed by having more mutant alleles, 47% vs. 29%,
p= .008.72 healthy normal controls
W 68 (94%), B & Other 4. (p= .4)
F 40 (56%), M 32 (44%). (p= .04)




TT 1 (1%), TC 27 (38%), CC 44 (61%) (p b .0001)
Pre-L-arginine treatment, study entry
66 ± 28, median 72, range 11–100
55 ± 31, median 50, range 0–100
57 ± 32, median 60, range 0–100
49 ± 31, median 44, range 0–100
33 ± 27, median 25, range 0–92
entry
4 (1–2 times/week) 5 (b1/week) 6 (0 over the 4 weeks)
5 (8%) 8 (14%) 10 (17%)
Fig. 2. Angina frequency during the past 4 weeks in 28 PVA patients who had Seattle Angina Questionnaire data at the pre-L-arginine treatment study entry, and after 1 and 5 months of
treatment with L-arginine (9 g/day).
Table 2
Effects of treatment with L-arginine (9 g/day)a on Seattle Angina Questionnaire scores in 28 patientsb with Prinzmetal's Angina.
Seattle Angina Questionnaire scores
Scores range 0 to 100, higher better.
Pre-L-arginine treatment,
study entry
1st follow-up on L-arginine
(median = 1 month)
2nd follow-up on L-arginine
(median = 5 months)
Mean ± SD Median Mean ± SD Median p Mean ± SD Median p
A. Physical ability score 61 ± 27 60 69 ± 26 71 .02 72 ± 22 72 .009
B. Symptom remission compared to 4 weeks ago 48 ± 30 50 76 ± 24 75 .0001 68 ± 33 75 .03
C. Angina frequency less during past 4 weeks 51 ± 32 50 65 ± 29 75 .001 66 ± 28 80 .01
D. Satisfaction with treatment for symptoms 50 ± 29 44 73 ± 28 81 b.0001 76 ± 25 81 .0002
E. Perception of overall life status 31 ± 30 25 53 ± 30 58 b.0001 56 ± 27 63 .0003
a L-Arginine (9 g/day) added on top of unchanged conventional treatment with calcium channel blockers–long acting nitrates.
b 28 patients had entry, 1st follow-up, and 2nd follow-up (p values, for comparisons with entry).
Fig. 1. eNOS T-786C genotypes and mutant allele frequency in 59 patients with Prinzmetal's Variant Angina (PVA) and in 72 healthy normal controls.
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Table 3
Change of angina scores from the pre-L-arginine treatment study entry to the last follow-up on L-arginine in 59 patients, by eNOS genotype (median values exhibited).
Seattle Questionnaire scores. Scores range
from 0 to 100, higher means better
All eNOS = CC eNOS = TC or TT p: compare score changes
between CC and (TC–TT),
adjusted for gender, age and
L-arginine treatment duration
n= 59 n= 15 n= 44
Duration on L-arginine treatment (months) 12 11 13
Score A (physical ability score)
At the pre-L-arginine study entry 72 53 81
On L-arginine 83 64 85
Change p= .0001 p= .01 p= .008 NS
Score B (symptom remission compared to 4 weeks ago)
At pre-L-arginine study entry 50 50 50
On L-arginine 75 50 88
Change p= .002 p= .1 p b .0001 p= .0002
Score C (angina frequency less during past 4 weeks)
At the pre-L-arginine study entry 60 60 60
80 70 80
Change p b .0001 p= .5 p b .0001 NS
Score D (satisfaction with treatment for symptoms)
At the pre-L-arginine study entry 44 50 44
On L-arginine 81 81 78
Change p b .0001 p= .003 p b .0001 NS
Score E (perception of overall life status)
At the pre-L-arginine study entry 25 33 25
On L-arginine 67 50 71
Change p b .0001 p= .002 p b .0001 NS
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status, using the SAQ (Table 1). At pre-L-arginine treatment study entry,
in 44% of the 59 patients, chest pain was daily, 4 or more times/day
in 25% and 1–3 times/day in 19%, despite maximal tolerated calcium
channel blocker–nitrates (Table 1).
Of the 59 patients, 22 had a previous MI and 37 did not (Table 1).
The eNOS genotype did not differ between the MI and no MI group;
p = 0.96. Of the 59 patients, 7 had ≥1 stent and 52 did not, and the
eNOS genotype did not differ between the 2 groups, p= 0.7. Of the 59
patients, with a median treatment duration of 12 months, no patients
had new myocardial infarctions and none had new coronary artery
stenting.
Table 2 displays SAQ scores at the pre-L-arginine treatment study
entry and at the ﬁrst and second follow-ups on L-arginine at 1 and
5 months. Compared to pre-treatment baseline, all 5 components of
the SAQ improved in 28 patients at 1 month (p ≤ .02 for all) and
5 months (p ≤ .03 for all) on treatment with L-arginine.
Comparing the patterns of daily chest pain at the pre-L-arginine
study entry, and after 1 and 5 months on L-arginine therapy, theTable 4
Regressionmodel of change in angina scores on the Seattle AnginaQuestionnaire from the pre-L
in 59 PVA patients.
Dependent variable n Signiﬁcant explanatory variab
Change of Score Aa 59 Intercept
Age at study entry
Change of Score Bb 59 Intercept
eNOS (CC = 0, TC or TT = 1)
Change of Score Cc 59 None
Change of Score Dd 59 None
Change of Score Ee 59 Intercept
Age at study entry
Regression model: stepwise selection from explanatory variables: gender, age, age at ﬁrst angi
a Physical ability score.
b Symptom remission compared to 4 weeks ago.
c Angina frequency during the past 4 weeks.
d Satisfaction with treatment for symptoms.
e Perception of overall life status.percentage of patients with angina ≥4 times per day fell from 36%
to 14% to 11%, and those with angina 1–3 times per day fell from 21%
to 18%, to 14%, Fig. 2. Conversely, the percentage of patients with no
weekly angina pain at pre-treatment entry, 7%, rose to 11% at 1 month
on L-arginine and to 14% at 5 months, Fig. 2.
Of the 59 patients with ≥1 follow-up visit on L-arginine, (which
included the 28 patients with ≥2 visits on L-arginine) at their last
follow-up after the 12 month therapy (median) with L-arginine, all
ﬁve components of the SAQ improved, p ≤ .002 for all, (column 1-
Table 3, Fig. 3). In those 15 patients whose eNOS genotype was CC
(wild type normal), median pre-treatment Score B was unchanged
after 11 months of L-arginine therapy, p = 0.1 (Table 3). However,
in 44 patients with eNOS TC (n = 32) or TT (n = 12), median pre-
treatment Score B rose at the 13 month follow-up, p ≤ .0001 (Table 3).
Comparing changes in score B on L-arginine treatment in the 15 CC vs.
44 TC–TT patients, the 44 TC–TT patients had a greater improvement
in Score B (p= .0002) (Table 3).
By stepwise regression, assessing the change in Seattle Question-
naire Score B from the pre-L-arginine study entry to last follow-up on-arginine treatment study entry to the last followup (amedian of 12months) on L-arginine
les Coefﬁcient estimate ± SE, p Partial R-squared
34.9 ± 11.0, p= .003
−0.45 ± 0.20, p= .03 8.2%
−15.0 ± 9.6, p= .1
44.0 ± 11.1, p= .0002 21.6%
60.7 ± 15.0, p= .0002
−0.62 ± 0.27, p= .03 8.4%
na, follow-up duration on L-arginine therapy, and eNOS genotype.
Fig. 3. Changes in the Seattle Angina Questionnaire Scores in 59 PVA patients from pre-L-
arginine treatment study entry and after 12 months (median) treatment with L-arginine
(9 g/day).
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tion was a signiﬁcant independent variable for remission of angina
symptoms (Table 4). For two of the 5 Seattle Questionnaire categories,
age was a negative determinant for improvement in anginal scores on
L-arginine, Table 4.
L-Arginine was well tolerated. Occasional nausea was the only
reported side effect of the medication.4. Discussion
Our current ﬁnding of enrichment of eNOS T786C mutant alleles in
59 predominantly Caucasian patients is the third report [10,11] in
Americans, and is congruent with previous reports in Japanese [15,39].
Discovery of the eNOS T-786Cmutation predisposing to coronary artery
spasm [10,11,35] is important since conventional therapy with calcium
channel blockers and long-acting nitrates fails to resolve intractable
angina in 20% to 60% of PVA patients [23,27,28]. Moreover, PVA is asso-
ciated with increased all-cause and cardiac mortality and myocardial
infarction [7]. In the current study, with amedian of 12months of treat-
mentwith L-arginine, none of the 59 patients sustained newmyocardial
infarctions and none had new coronary artery stents.
We had previously reported that L-arginine treatment improved
peripheral circulation in patients with Buerger's diseasewith peripheral
arterial vasospasmwho also had the eNOS T-786Cmutation [40]. Keep-
ing this in mind we postulated that L-arginine would effectively reduce
coronary artery spasm-angina in PVAwhich has the same eNOS T-786C
mutation. Our previous studies [10,11], current report, and Blum et al.
[30] suggest that L-arginine, an amino-acid precursor for NO [20], effec-
tively reduces intractable angina in PVA patients. Dose ranging studies
were not performed in the current report, nor in the two previous stud-
ies [10,11] and should be done in the future.In the current study, in 28 patients, after 1 and 5 months of therapy
with 9 g L-arginine/day, all 5 components of the Seattle Anginal
Questionnaire improved, p ≤ .03 for all. Similarly in 59 patients with
median L-arginine treatment of 12 months, all 5 components of the
Seattle score improved (p ≤ .002 for all). The eNOS genotype was a sig-
niﬁcant independent predictor of angina symptom remission (partial
R2 = 21.6%, p = .0002), with greater remission increasing in patients
who had the T786C mutation (TC or TT). In PVA patients with intrac-
table angina despite conventional nitrate–calcium channel blocker
therapy, L-arginine appears to safely provide substantial symptomatic
relief.
5. Limitations
An optimal study design would be double-blind and randomized,
and stratiﬁed by the eNOS T786C genotype into the CC, TC, and TT
groups, to determine if response to L-argininewas associatedwith geno-
type. However, this study design would require ≥26 patients per geno-
type group (total 78), based on the power calculations for the current
report. A control group of PVA patients given placebo would further
be valuable because some patients may experience spontaneous ame-
lioration of their symptoms over a long follow-up time.
Using a subjective assessment of symptoms and quality of life via a
formal questionnaire (Seattle Angina Questionnaire) may not give ob-
jective evidence of diminution or absence of attacks of myocardial
ischemia, if ischemic attacks occur without symptoms. Long-term ECG
monitoring devicesmight be used in the future to assess disease control.
The median daily doses of the calcium-channel blocking agents in
the 59 PVA patients were relatively modest, but were the prescribed
doses by their cardiologists.
The use of a single 9 g/day dose of L-arginine did not allow assess-
ment of stepped dose adjustment starting at a lower level, and did not
allow assessment of doses above 9 g/day.
Our study is limited by the small sample size, dictated by our selec-
tion of very well documented PVA patients with intractable angina
despite conventional calcium channel blocker–long acting nitrate ther-
apy. Being unblinded, symptom relief may in part reﬂect placebo effect.
Sample sizes that are orders of magnitude greater are needed to gener-
ate robust data when the genetic contribution is modest [41]. Double-
blind, placebo-controlled clinical trials of L-arginine supplementation
should be considered in those patients whose PVA cannot be satisfacto-
rily treated with currently available therapies.
6. Conclusion
The eNOS T-786C mutation appears to facilitate CAS via reduced
NO production, a condition susceptible to treatment with L-arginine.
In patients with the eNOS T-786C mutation, intractable angina despite
conventional calcium channel blocker–nitrate therapy may be amelio-
rated by L-arginine.
Conﬂict of interest
The authors state that there are no conﬂicts of interest, including
related consultancies, shareholdings, and funding grants.
Acknowledgments
This study was supported in part by the Lipoprotein Research Fund
of the Jewish Hospital of Cincinnati (CJ Glueck, MD, Director).
References
[1] Japanese Circulation Society (JCS) JointWorking Groups for Guidelines for Diagnosis
and Treatment of Cardiovascular Diseases, Guidelines for the clinical application of
echocardiography (JCS 2005), J. Cardiol. 48 (2006) 439–475.
19C.J. Glueck et al. / IJC Metabolic & Endocrine 8 (2015) 13–19[2] M. Prinzmetal, R. Kennamer, R. Merliss, T. Wada, N. Bor, Angina pectoris. I. A variant
form of angina pectoris; preliminary report, Am. J. Med. 27 (1959) 375–388.
[3] G.A. Lanza, G. Careri, F. Crea, Mechanisms of coronary artery spasm, Circulation 124
(2011) 1774–1782.
[4] H. Kaneda, J. Taguchi, Y. Kuwada, et al., Coronary artery spasm and the polymor-
phisms of the endothelial nitric oxide synthase gene, Circ. J. 70 (2006) 409–413.
[5] Y. Kusama, E. Kodani, A. Nakagomi, et al., Variant angina and coronary artery spasm:
the clinical spectrum, pathophysiology, and management, J. Nippon Med. Sch. 78
(2011) 4–12.
[6] Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary
spastic angina) (JCS 2008): digest version, Circ. J. 74 (2010) 1745–1762.
[7] J. Figueras, E. Domingo, I. Ferreira, R.M. Lidon, D. Garcia-Dorado, Persistent angina
pectoris, cardiac mortality and myocardial infarction during a 12 year follow-up in
273 variant angina patients without signiﬁcant ﬁxed coronary stenosis, Am. J.
Cardiol. 110 (2012) 1249–1255.
[8] K. Kugiyama, H. Yasue, K. Okumura, et al., Nitric oxide activity is deﬁcient in spasm
arteries of patients with coronary spastic angina, Circulation 94 (1996) 266–271.
[9] C. Jia, T. Liu, Z. Liu, M. Li, M. Hu, Joint effects of eNOS gene T-786C and ADH2
Arg47His polymorphisms on the risk of premature coronary artery disease, Thromb.
Res. 120 (2007) 679–684.
[10] C.J. Glueck, J. Munjal, A. Khan, M. Umar, P.Wang, Endothelial nitric oxide synthase T-
786C mutation, a reversible etiology of Prinzmetal's angina pectoris, Am. J. Cardiol.
105 (2010) 792–796.
[11] C.J. Glueck, A. Valdes, D. Bowe, S. Munsif, P. Wang, The endothelial nitric oxide syn-
thase T-786c mutation, a treatable etiology of Prinzmetal's angina, Transl. Res. 162
(2013) 64–66.
[12] S.Y. Yoo, J.Y. Kim, Recent insights into themechanisms of vasospastic angina, Korean
Circ. J. 39 (2009) 505–511.
[13] M. Nakayama, M. Yoshimura, T. Sakamoto, et al., Synergistic interaction of T-786–NC
polymorphism in the endothelial nitric oxide synthase gene and smoking for an
enhanced risk for coronary spasm, Pharmacogenetics 13 (2003) 683–688.
[14] O. Mayer Jr., J. Filipovsky, M. Pesta, R. Cifkova, M. Dolejsova, J. Simon, The interaction
of endothelial nitric oxide synthase polymorphism and current smoking in terms of
increased arterial stiffness, Physiol. Res. 59 (2010) 529–536.
[15] M. Nakayama, M. Yoshimura, T. Sakamoto, et al., A -786TNC polymorphism in the
endothelial nitric oxide synthase gene reduces serum nitrite/nitrate levels from
the heart due to an intracoronary injection of acetylcholine, Pharmacogenet.
Genomics 16 (2006) 339–345.
[16] A. Maseri, A. L'Abbate, G. Baroldi, et al., Coronary vasospasm as a possible cause
of myocardial infarction. A conclusion derived from the study of “preinfarction”
angina, N. Engl. J. Med. 299 (1978) 1271–1277.
[17] A. Maseri, S. Severi, M.D. Nes, et al., “Variant” angina: one aspect of a continuous
spectrum of vasospastic myocardial ischemia. Pathogenetic mechanisms, estimated
incidence and clinical and coronary arteriographic ﬁndings in 138 patients, Am. J.
Cardiol. 42 (1978) 1019–1035.
[18] M. Nakamura, A. Takeshita, Y. Nose, Clinical characteristics associated with myocar-
dial infarction, arrhythmias, and sudden death in patients with vasospastic angina,
Circulation 75 (1987) 1110–1116.
[19] H. Yasue, K. Kugiyama, Coronary spasm: clinical features and pathogenesis, Intern.
Med. 36 (1997) 760–765.
[20] M. Bory, F. Pierron, D. Panagides, J.L. Bonnet, S. Yvorra, L. Desfossez, Coronary artery
spasm in patients with normal or near normal coronary arteries. Long-term follow-
up of 277 patients, Eur. Heart J. 17 (1996) 1015–1021.
[21] S.B. Freedman, D.R. Richmond, M. Alwyn, D.T. Kelly, Late follow-up (41 to
102 months) of medically treated patients with coronary artery spasm and minor
atherosclerotic coronary obstructions, Am. J. Cardiol. 57 (1986) 1261–1263.[22] M.J. Hung, M.Y. Hung, C.W. Cheng, N.I. Yang, W.J. Cherng, Clinical characteristics
of patients with exercise-induced ST-segment elevation without prior myocardial
infarction, Circ. J. 70 (2006) 254–261.
[23] d.L. JA ORR (Ed.), Hurst's the Heart, 12th ed.McGraw-Hill, New York, 2008.
[24] Pinto DS BJ, Crea F.. Variant angina. [Internet]; Available from: http://
www.uptodate.com/contents/variant-angina?source=search_result&search=
variant+angina&selectedTitle=1%7E103.
[25] H. Yasue, H. Nakagawa, T. Itoh, E. Harada, Y. Mizuno, Coronary artery spasm—clinical
features, diagnosis, pathogenesis, and treatment, J. Cardiol. 51 (2008) 2–17.
[26] M. Kosugi, A. Nakagomi, T. Shibui, et al., Effect of long-term nitrate treatment on
cardiac events in patients with vasospastic angina, Circ. J. 75 (2011) 2196–2205.
[27] Y. Murase, Y. Yamada, A. Hirashiki, et al., Genetic risk and gene–environment inter-
action in coronary artery spasm in Japanese men and women, Eur. Heart J. 25
(2004) 970–977.
[28] F. Pierron, D. Panagides, J.L. Bonnet, S. Yvorra, L. Desfossez, M. Bory, Spasm of normal
or irregular coronary arteries. Long-term outcome of 277 patients, Arch. Mal. Coeur
Vaiss. 88 (1995) 1819–1825.
[29] P. Piatti, G. Fragasso, L.D. Monti, et al., Acute intravenous L-arginine infusion
decreases endothelin-1 levels and improves endothelial function in patients with
angina pectoris and normal coronary arteriograms: correlation with asymmetric
dimethylarginine levels, Circulation 107 (2003) 429–436.
[30] A. Blum, R. Porat, U. Rosenschein, et al., Clinical and inﬂammatory effects of dietary
L-arginine in patients with intractable angina pectoris, Am. J. Cardiol. 83 (1999)
1488–1490 (A8).
[31] P. Angelini, C. Uribe, P. Lozano, Differential local spasticity in myocardial bridges,
Tex. Heart Inst. J. 39 (2012) 384–388.
[32] S.P. Schulman, L.C. Becker, D.A. Kass, et al., L-Arginine therapy in acute myocardial
infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE
MI) randomized clinical trial, JAMA 295 (2006) 58–64.
[33] T. Sun, W.B. Zhou, X.P. Luo, Y.L. Tang, H.M. Shi, Oral L-arginine supplementation
in acute myocardial infarction therapy: a meta-analysis of randomized controlled
trials, Clin. Cardiol. 32 (2009) 649–652.
[34] J.A. Spertus, J.A. Winder, T.A. Dewhurst, et al., Development and evaluation of the
Seattle Angina Questionnaire: a new functional status measure for coronary artery
disease, J. Am. Coll. Cardiol. 25 (1995) 333–341.
[35] V.V. Balasa, R.A. Gruppo, C.J. Glueck, et al., The relationship of mutations in the
MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrom-
bin, and PAI-1 in children and adults, Thromb. Haemost. 81 (1999) 739–744.
[36] V.V. Balasa, R.A. Gruppo, C.J. Glueck, et al., Legg–Calve–Perthes disease and
thrombophilia, J. Bone Joint Surg. Am. 86-A (2004) 2642–2647.
[37] C.J. Glueck, R.A. Freiberg, J. Oghene, R.N. Fontaine, P. Wang, Association between the
T-786C eNOS polymorphism and idiopathic osteonecrosis of the head of the femur,
J. Bone Joint Surg. Am. 89 (2007) 2460–2468.
[38] C. Fatini, F. Soﬁ, A.M. Gori, et al., Endothelial nitric oxide synthase -786TNC, but not
894GNT and 4a4b, polymorphism inﬂuences plasma homocysteine concentrations
in persons with normal vitamin status, Clin. Chem. 51 (2005) 1159–1164.
[39] M. Nakayama, H. Yasue, M. Yoshimura, et al., T-786–NC mutation in the 5′-ﬂanking
region of the endothelial nitric oxide synthase gene is associated with coronary
spasm, Circulation 99 (1999) 2864–2870.
[40] C.J. Glueck, M. Haque, M. Winarska, et al., Stromelysin-1 5A/6A and eNOS T-786C
polymorphisms, MTHFR C677T and A1298C mutations, and cigarette–cannabis
smoking: a pilot, hypothesis-generating study of gene–environment pathophysio-
logical associations with Buerger's disease, Clin. Appl. Thromb. Hemost. 12 (2006)
427–439.
[41] L.R. Cardon, J.I. Bell, Association study designs for complex diseases, Nat. Rev. Genet.
2 (2001) 91–99.
